Saira Ramasastry, a director at Mirum Pharmaceuticals, sold 2,000 shares of common stock for a total of $218,940 on May 15, 2026.
The shares were sold at $109.47 each. The stock has since fallen to $95.49 but remains up 113% over the past year.
The sale was executed under a Rule 10b5-1 trading plan adopted on September 18, 2025.
Concurrently, Ramasastry acquired 2,000 shares by exercising stock options at $23.51 per share, totaling $47,020.
Following these transactions, Ramasastry holds no direct shares. According to Bond.az analysis, the stock may be overvalued, and analysts do not expect profitability this year.
In other news, Mirum reported Q1 2026 earnings with revenue of $159.9 million, beating estimates, though EPS missed expectations due to acquisition costs.
